← back to search

Srinath Sanda

University of California, San Francisco · US
Area of research
Genetics · Immunology
Research interest
Research interests include Diabetes and associated disorders, Diabetes Management and Research, Pancreatic function and diabetes, and T-cell and B-cell Immunology.
h-index
37
citations
4,385
works
94
NIH funding
primary concept
email

Recent publications

Gut microbial bile and amino acid metabolism associate with peanut oral immunotherapy failure
Nature Communications 2025cited by 6position: middledoi
A phase 2 randomized trial with autologous polyclonal expanded regulatory T cells in children with new-onset type 1 diabetes
Science Translational Medicine 2024cited by 60position: middledoi
Effects of combination treatment with tezepelumab and allergen immunotherapy on nasal responses to allergen: A randomized controlled trial
Journal of Allergy and Clinical Immunology 2022cited by 79position: lastdoi
Imatinib therapy for patients with recent-onset type 1 diabetes: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
The Lancet Diabetes & Endocrinology 2021cited by 131position: middledoi
IL-6 receptor blockade does not slow β cell loss in new-onset type 1 diabetes
JCI Insight 2021cited by 58position: middledoi
Diabetic ketoacidosis drives <scp>COVID‐19</scp> related hospitalizations in children with type <scp>1</scp> diabetes
Journal of Diabetes 2021cited by 37position: middledoi
Inequities in Diabetic Ketoacidosis Among Patients With Type 1 Diabetes and COVID-19: Data From 52 US Clinical Centers
The Journal of Clinical Endocrinology & Metabolism 2020cited by 70position: middledoi
Sensitive detection of multiple islet autoantibodies in type 1 diabetes using small sample volumes by agglutination-PCR
PLoS ONE 2020cited by 46position: middledoi
Survival in a bad neighborhood: pancreatic islets in cystic fibrosis
Journal of Endocrinology 2019cited by 62position: middledoi
Islet Interleukin-1β Immunoreactivity Is an Early Feature of Cystic Fibrosis That May Contribute to β-Cell Failure
Diabetes Care 2018cited by 79position: lastdoi
Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials
The Lancet 2013cited by 354position: middledoi
Rapamycin/IL-2 Combination Therapy in Patients With Type 1 Diabetes Augments Tregs yet Transiently Impairs β-Cell Function
Diabetes 2012cited by 307position: middledoi
Diabetes promotes an inflammatory macrophage phenotype and atherosclerosis through acyl-CoA synthetase 1
Proceedings of the National Academy of Sciences 2012cited by 306position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Rebecca L. Hull · University of Dundee2 papers (2018–2019)Carla J. Greenbaum · Center for Infectious Disease Research2 papers (2012–2020)Lisa M. Wheatley · National Institute of Allergy and Infectious Diseases2 papers (2022–2025) · 1 papers (2020–2020)Anuradha Vivekanandan‐Giri · University Medical Center1 papers (2012–2012)Sharon McNamara · Seattle Children's Hospital1 papers (2018–2018)Fuad M. Baroody · University of Chicago1 papers (2022–2022)Jane H. Buckner · Seattle University1 papers (2012–2012)Rosalind Coleman · University of North Carolina at Chapel Hill1 papers (2012–2012)Jonathan Corren · APLA Health1 papers (2022–2022)Harold S. Nelson · University of Colorado Denver1 papers (2022–2022)John F. Engelhardt · University of Alabama at Birmingham1 papers (2019–2019)Alan Chait · University of Washington1 papers (2012–2012) · 1 papers (2022–2022)Jeffrey A. Bluestone · Fort Ross Conservancy1 papers (2012–2012) · 1 papers (2022–2022)Cheng‐ting Tsai · Enable Biosciences (United States)1 papers (2020–2020)Charles N. Serhan · Harvard University1 papers (2012–2012)Stephen A. Tilles · University of San Francisco1 papers (2022–2022)Ronald L. Gibson · Seattle Children's Hospital1 papers (2018–2018)